{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:06:47Z","timestamp":1789718807067,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2025.102899","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T22:48:56Z","timestamp":1739400536000},"page":"102899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms \u2013 A systematic review"],"prefix":"10.1016","volume":"134","author":[{"given":"Giulia","family":"Arrivi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rinzivillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-4289","authenticated-orcid":false,"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ctrv.2025.102899_b0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102899_b0010","doi-asserted-by":"crossref","unstructured":"Xu Z, Wang L, Dai S, et al. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open. 2021;4(9):e2124750. Published 2021 Sep 1. doi: 10.1001\/jamanetworkopen.2021.24750.","DOI":"10.1001\/jamanetworkopen.2021.24750"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2025.102899_b0020","doi-asserted-by":"crossref","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343. doi: 10.1111\/jne.13343.","DOI":"10.1111\/jne.13343"},{"key":"10.1016\/j.ctrv.2025.102899_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102560","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists","volume":"117","author":"La Salvia","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102899_b0030","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102899_b0035","doi-asserted-by":"crossref","unstructured":"Capdevila J, Ducreux M, Garc\u00eda Carbonero R, et al. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022;112(12):1155-1167. doi: 10.1159\/000524988.","DOI":"10.1159\/000524988"},{"key":"10.1016\/j.ctrv.2025.102899_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102803","article-title":"Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors","volume":"129","author":"Panzuto","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.102899_b0045","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-e130.","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102899_b0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2025.102899_b0055","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102899_b0060","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin \u00b1 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0065","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1245\/s10434-018-6468-8","article-title":"Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases","volume":"25","author":"Cloyd","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11605-016-3270-4","article-title":"Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors","volume":"21","author":"Prakash","year":"2017","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102899_b0080","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T","article-title":"Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)","volume":"34","author":"Schein","year":"1974","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102899_b0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000421-198808000-00015","article-title":"A phase II trial of streptozotocin and adriamycin in advanced APUD tumors","volume":"11","author":"Frame","year":"1988","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102899_b0090","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102899_b0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","article-title":"Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors","volume":"27","author":"McCollum","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102899_b0110","doi-asserted-by":"crossref","unstructured":"Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas [published correction appears in J Clin Oncol. 2005 Jan 1;23(1):248]. J Clin Oncol. 2004;22(23):4762-4771. doi: 10.1200\/JCO.2004.04.024.","DOI":"10.1200\/JCO.2004.04.024"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102899_b0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejca.2003.09.035","article-title":"The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?","volume":"40","author":"Delaunoit","year":"2004","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000117575","article-title":"Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors","volume":"88","author":"Fjallskog","year":"2008","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102899_b0125","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102899_b0130","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.ejca.2014.10.002","volume":"50","author":"Ducreux","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102899_b0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00535-014-1006-3","article-title":"Streptozocin chemotherapy for advanced\/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan","volume":"50","author":"Aoki","year":"2015","journal-title":"J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102899_b0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2025.102899_b0145","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1002\/cncr.29517","article-title":"Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice","volume":"121","author":"Dussol","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102899_b0150","doi-asserted-by":"crossref","unstructured":"Krug S, Boch M, Daniel H, et al. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One. 2015;10(12):e0143822. Published 2015 Dec 2. doi: 10.1371\/journal.pone.0143822.","DOI":"10.1371\/journal.pone.0143822"},{"key":"10.1016\/j.ctrv.2025.102899_b0155","doi-asserted-by":"crossref","unstructured":"Clewemar Antonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology. 2016;103(3-4):345-353. doi: 10.1159\/000439086.","DOI":"10.1159\/000439086"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pan.2016.12.006","article-title":"Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy","volume":"17","author":"Krug","year":"2017","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102899_b0165","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.21873\/anticanres.11590","article-title":"Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors","volume":"37","author":"Krug","year":"2017","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-018-3700-y","article-title":"Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET","volume":"83","author":"Hijioka","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000457955","article-title":"Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index \u226510%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)","volume":"106","author":"Roquin","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102899_b0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-018-3656-y","article-title":"Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy","volume":"82","author":"Shibuya","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0185","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00432-019-03109-5","article-title":"Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms","volume":"146","author":"Ono","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102899_b0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12020-019-01941-w","article-title":"Extended cycle streptozotocin\/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors","volume":"65","author":"Schrader","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0195","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-021-02859-y","article-title":"Streptozocin\/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy","volume":"75","author":"Lahner","year":"2022","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102899_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.10.014","article-title":"Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study","volume":"45","author":"Legoux","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.102899_b0205","doi-asserted-by":"crossref","unstructured":"Komoto I, Kokudo N, Aoki T, et al. Phase I\/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors [published correction appears in Jpn J Clin Oncol. 2022 Nov 3;52(11):1358. doi: 10.1093\/jjco\/hyac156]. Jpn J Clin Oncol. 2022;52(7):716-724. doi: 10.1093\/jjco\/hyac048.","DOI":"10.1093\/jjco\/hyac048"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000514339","article-title":"Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors","volume":"112","author":"Rogers","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000518895","article-title":"Localization Defines Streptozotocin\/5-FU Response in Primary Pancreatic Neuroendocrine Tumours","volume":"112","author":"Reher","year":"2022","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2025.102899_b0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-34666-y","article-title":"MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens","author":"Yagi","year":"20231317535","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jjco\/hyae026","article-title":"Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice","volume":"54","author":"Murakami","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102899_b0230","doi-asserted-by":"crossref","unstructured":"Petersen SS, M\u00f8ller S, Slott C, et al. Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000-2020. Cancers (Basel). 2024;16(6):1190. Published 2024 Mar 18. doi: 10.3390\/cancers16061190.","DOI":"10.3390\/cancers16061190"},{"key":"10.1016\/j.ctrv.2025.102899_b0235","doi-asserted-by":"crossref","unstructured":"Frizziero M, Spada F, Lamarca A, et al. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. Neuroendocrinology. 2019;109(2):100-112. doi: 10.1159\/000497336.","DOI":"10.1159\/000497336"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102899_b0240","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1159\/000511905","article-title":"A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations","volume":"111","author":"Elvebakken","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"Suppl 16","key":"10.1016\/j.ctrv.2025.102899_b0245","doi-asserted-by":"crossref","first-page":"S4216","DOI":"10.1200\/jco.2005.23.16_suppl.4216","article-title":"Effective treatment of neuroendocrine tumors with temozolomide and capecitabine","volume":"23","author":"Fine","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102899_b0250","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0255","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12020-020-02421-2","article-title":"Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis","volume":"72","author":"Spada","year":"2021","journal-title":"Endocrine"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102899_b0260","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.2147\/CMAR.S372776","article-title":"Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis","volume":"21","author":"Arrivi","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102899_b0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000365514","article-title":"Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms","volume":"100","author":"Schmitt","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102899_b0275","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102899_b0280","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4099","article-title":"Identification of response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","author":"Strosberg","year":"201533154099","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102899_b0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/onco.13686","article-title":"Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.102899_b0290","doi-asserted-by":"crossref","unstructured":"Spada F, Antonuzzo L, Marconcini R, et al. Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multicenter retrospective analysis, Journal of Clinical Oncology. 33. e15174-e15174. 10.1200\/jco.2015.33.15_suppl.e15174.","DOI":"10.1200\/jco.2015.33.15_suppl.e15174"},{"key":"10.1016\/j.ctrv.2025.102899_b0295","doi-asserted-by":"crossref","unstructured":"Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. J Oncol. 2019;2019:9032753. Published 2019 Feb 20. doi: 10.1155\/2019\/9032753.","DOI":"10.1155\/2019\/9032753"},{"key":"10.1016\/j.ctrv.2025.102899_b0300","article-title":"Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)","author":"Thomas","year":"2020121206","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100119","article-title":"Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study","volume":"6","author":"Jeong","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.102899_b0310","doi-asserted-by":"crossref","unstructured":"Butt BP, Stokmo HL, Ladekarl M, et al. Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas. Ann Oncol 2021;32(Suppl 5):Abstract 1108P.","DOI":"10.1016\/j.annonc.2021.08.190"},{"key":"10.1016\/j.ctrv.2025.102899_b0315","doi-asserted-by":"crossref","unstructured":"Borghesani M, Reni A, Lauricella E, et al. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. J Natl Compr Canc Netw. 2024;22(5):e247005. Published 2024 May 14. doi: 10.6004\/jnccn.2024.7005.","DOI":"10.6004\/jnccn.2024.7005"},{"key":"10.1016\/j.ctrv.2025.102899_b0320","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine and Adrenal Tumors, Version 2.2024 \u2014 August 1, 2024,https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf."},{"key":"10.1016\/j.ctrv.2025.102899_b0325","doi-asserted-by":"crossref","first-page":"S1412","DOI":"10.1016\/j.annonc.2022.08.044","article-title":"LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)","volume":"33","author":"Salazar","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102899_b0330","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/bjs\/znaa141","article-title":"Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis","volume":"108","author":"Ricci","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2025.102899_b0335","doi-asserted-by":"crossref","unstructured":"Opali\u0144ska M, Sowa-Staszczak A, Grochowska A, Olearska H, Hubalewska-Dydejczyk A. Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors. Front Oncol. 2021;11:687925. Published 2021 Nov 12. doi: 10.3389\/fonc.2021.687925.","DOI":"10.3389\/fonc.2021.687925"},{"key":"10.1016\/j.ctrv.2025.102899_b0340","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study","volume":"111(9):znae178","author":"Partelli","year":"2024","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0345","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The Role of Capecitabine\/Temozolomide in Metastatic Neuroendocrine Tumors","volume":"21","author":"Ramirez","year":"2016","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.ctrv.2025.102899_b0350","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102899_b0355","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0360","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000345369","article-title":"Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor","volume":"5","author":"Devata","year":"2012","journal-title":"Case Rep Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0365","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MPA.0000000000001500","article-title":"Neoadjuvant Capecitabine\/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors","volume":"49","author":"Squires","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2025.102899_b0370","doi-asserted-by":"crossref","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [published correction appears in N Engl J Med. 2011 Mar 17;364(11):1082]. N Engl J Med. 2011;364(6):501-513. doi: 10.1056\/NEJMoa1003825.","DOI":"10.1056\/NEJMx110017"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102899_b0375","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ctrv.2025.102899_b0380","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0385","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Walter","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.102899_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102261","article-title":"Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis","volume":"99","author":"Trillo Aliaga","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.102899_b0395","doi-asserted-by":"crossref","unstructured":"Walter, T. et al. LBA54 - Alkylating agent-based vs Oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: a randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network, Annals of Oncology, Volume 34, S1292 - S1293.","DOI":"10.1016\/j.annonc.2023.10.048"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102899_b0400","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102899_b0405","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1535-7163.MCT-06-0106","article-title":"Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma","volume":"5","author":"Maxwell","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102899_b0410","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1750-3639.2008.00153.x","article-title":"Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker","volume":"18","author":"Preusser","year":"2008","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102899_b0415","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ijc.20575","article-title":"Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors","volume":"113","author":"M\u00f6llemann","year":"2005","journal-title":"Int J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:27:50Z","timestamp":1744190870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":83,"alternative-id":["S0305737225000210"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102899","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102899"}}